Resolve relative to pharmacy deserts
Generates a plain-language summary of the bill text and history.
| Date | Branch | Action |
|---|---|---|
| 6/16/2025 | Senate | Resolve reported favorably by committee and referred to the committee on Senate Ways and Means |
| 5/22/2025 | Joint | Hearing scheduled for 06/02/2025 from 11:00 AM-03:00 PM in Gardner Auditorium |
| 2/27/2025 | House | House concurred |
| 2/27/2025 | Senate | Referred to the committee on Health Care Financing |
No additional cosponsors.
| Committee | Recommendation | Vote |
|---|---|---|
| J24 | Favorable | — |
| Committee | Fiscal Amount |
|---|---|
| J24 | {'FiscalType': None, 'Amount': 'More Than 100,000.00 '} |
Resolved, SECTION 1. (a) The office of health resource planning established in section 22 of chapter 6D of the General Laws, inserted by section 22 of chapter 343 of the Acts of 2024, shall conduct a focused assessment on supply, distribution and capacity of pharmacy and pharmacological services pursuant to subsection (b) of said section 22. The office, when conducting its focused assessment, shall also identify the number of existing and potential pharmacy deserts in the commonwealth and conduct an analysis of their impact or potential impact on access to pharmacy and pharmacological services for residents located in the identified areas. For the purposes of this section, a “pharmacy desert” shall mean an area where there is no or limited access to pharmacies due to factors such as: (i) geographic location, specifically areas where the nearest pharmacy is more than 1 mile away in urban areas, more than 5 miles away in suburban areas and more than 10 miles away in rural areas; (ii) distance and travel time, defined as travel time exceeding 15 minutes by car or 30 minutes by public transportation; and (iii) limited access to transportation, both public and private, including areas with infrequent public transit services or where at least 20 per cent of the population lacks access to private vehicles. (b) Not later than September 1, 2026, the office shall present to the board of the health policy commission its findings based on the focused assessment conducted under subsection (a) and file a report of its findings with the clerks of the senate and house of representatives, the house and senate committees on ways and means, the joint committee on health care financing, the center for health information and analysis, the health policy commission and the department of public health. In addition to the findings required by paragraph (2) of subsection (b) of section 22, report of the office shall analyze the impact or potential impact of pharmacy deserts identified by the focused assessment, including, but not limited: (i) an assessment on impacted neighborhoods and patient populations; (ii) an assessment on the impact of pharmacy deserts on access to medications and health care outcomes; (iii) an assessment of the geographical and financial barriers to obtaining medications faced by individuals living in pharmacy deserts; (iv) an assessment of the average distance and travel time to a pharmacy from an impacted neighborhood, and the transportation options available; (v) an assessment on the impact of pharmacy deserts on overall health care costs, including the costs of emergency department visits and hospitalizations; (vi) an assessment on the impact of pharmacy benefit manager business practices in contributing to the closures of pharmacies across the commonwealth; and (vii) policy recommendations to address current pharmacy deserts and limit the creation of new ones.
Resolved, SECTION 1. (a) The office of health resource planning established in section 22 of chapter 6D of the General Laws, inserted by section 22 of chapter 343 of the Acts of 2024, shall conduct a focused assessment on supply, distribution and capacity of pharmacy and pharmacological services pursuant to subsection (b) of said section 22. The office, when conducting its focused assessment, shall also identify the number of existing and potential pharmacy deserts in the commonwealth and conduct an analysis of their impact or potential impact on access to pharmacy and pharmacological services for residents located in the identified areas. For the purposes of this section, a “pharmacy desert” shall mean an area where there is no or limited access to pharmacies due to factors such as: (i) geographic location, specifically areas where the nearest pharmacy is more than 1 mile away in urban areas, more than 5 miles away in suburban areas and more than 10 miles away in rural areas; (ii) distance and travel time, defined as travel time exceeding 15 minutes by car or 30 minutes by public transportation; and (iii) limited access to transportation, both public and private, including areas with infrequent public transit services or where at least 20 per cent of the population lacks access to private vehicles. (b) Not later than September 1, 2026, the office shall present to the board of the health policy commission its findings based on the focused assessment conducted under subsection (a) and file a report of its findings with the clerks of the senate and house of representatives, the house and senate committees on ways and means, the joint committee on health care financing, the center for health information and analysis, the health policy commission and the department of public health. In addition to the findings required by paragraph (2) of subsection (b) of section 22, report of the office shall analyze the impact or potential impact of pharmacy deserts identified by the focused assessment, including, but not limited: (i) an assessment on impacted neighborhoods and patient populations; (ii) an assessment on the impact of pharmacy deserts on access to medications and health care outcomes; (iii) an assessment of the geographical and financial barriers to obtaining medications faced by individuals living in pharmacy deserts; (iv) an assessment of the average distance and travel time to a pharmacy from an impacted neighborhood, and the transportation options available; (v) an assessment on the impact of pharmacy deserts on overall health care costs, including the costs of emergency department visits and hospitalizations; (vi) an assessment on the impact of pharmacy benefit manager business practices in contributing to the closures of pharmacies across the commonwealth; and (vii) policy recommendations to address current pharmacy deserts and limit the creation of new ones.